Telehealth platforms that provide diagnostic tests, pharmaceutical products, dietary supplements, or other specialty health products – as well as the clinical consultations necessary for the prescription of/recommendation for those products – exist in a unique regulatory environment. The FTC is starting to target these platforms with enforcement actions around alleged marketing and advertising violations, however, and the FDA may not be far behind.

Referent: Rachael G. Pontikes Emily L. Hussey Monique N. Bhargava

Veranstaltungsart: Webinar, CLE / CPD

Startdatum / -uhrzeit:
1 May 2024, 2:30 PM EDT
Enddatum / -uhrzeit:
1 May 2024, 3:30 PM EDT

Join us for an engaging presentation:

  • Examining the FTC and FDA regulations and guidances applicable to these sort of telehealth platforms
  • Discussing recent enforcement actions against such platforms and what other platforms can learn from these actions
  • Providing a brief overview of the scope and process behind a marketing review and the protection it can offer such platforms

CLE Information: This program is presumptively approved for 1.0 CLE credit in California, Connecticut, Illinois, New Jersey, New York, Pennsylvania, Texas and West Virginia. Applications for CLE credit will be filed in Delaware, Florida, Ohio, and Virginia. Attendees who are licensed in other jurisdictions will receive a uniform certificate of attendance but Reed Smith only provides credit for the states listed. Please allow 4-6 weeks after the program to receive a certificate of attendance.